Gemcitabine and Cisplatin Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

Zhejiang Cancer Hospital1
Second Affiliated Hospital, School of Medicine, Zhejiang University1
Fudan University1

Indications

Cancer3
Liver Disease1
Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma1
Advanced Cholangiocarcinoma1
Biliary Tract Carcinoma1

Other3 trials

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

N/A

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Phase 2

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.